Your search history is turned on.
Date: March 28, 2024 Jurisdictions: Alberta, Ontario
Create participation fee form FORM 13-502F1 CLASS 1 AND CLASS 3B REPORTING ISSUERS PARTICIPATION FEE MANAGEMENT CERTIFICATION I, JEN, Jean, an officer of the reporting issuer noted below have examined this Form 13-502F1 (the Form) being submitted hereunder to the Ontario Securities Commission and certify that to my knowledge, having exercised reasonable dil...
Date: March 28, 2024 Jurisdictions: Alberta, British Columbia, Ontario
GeneTether - 52-109FV1 Certificate for Annual Statements (CFO) 2023 (conformed) (04694964).DOCX {04694964;1} Form 52-109FV1 Certification of Annual Filings Venture Issue Basic Certificate I, Jean Jen, Chief Financial Officer of GeneTether Therapeutics Inc., certify the following: 1. Review: I have reviewed the AIF, if any, annual financial ...
Create participation fee form Note: [01 Mar 2017] The following is a consolidation of 13-501F1. It incorporates amendments to this document that came into effect on March 1, 2017. This consolidation is provided for your convenience and should not be relied on as authoritative. FORM 13-501F1 CLASS 1 REPORTING ISSUERS AND CLASS 3B REPORTING ISSUERS PARTICIPATI...
GeneTether - 52-109 Certificate for Annual Statements (CEO) 2023 (conformed) (04694970).DOCX {04694970;1} Form 52-109FV1 Certification of Annual Filings Venture Issue Basic Certificate I, Roland Boivin, Chief Executive Officer of GeneTether Therapeutics Inc., certify the following: 1. Review: I have reviewed the AIF, if any, annual financi...
GeneTether - MDA FY2023 Draft 5 March 21 {04685091;1} GeneTether Therapeutics Inc. Managements Discussion and Analysis For the Year Ended December 31, 2023 Date of Report: March 28, 2024 {04685091;1} 1 MANAGEMENTS DISCUSSION AND ANALYSIS The following managements discussion and analysis (MD&A) ...
Genetether Therapeutics Inc FS 2023 DRAFT v6 March 22 Consolidated financial statements GeneTether Therapeutics Inc. For the years ended December 31, 2023 and 2022 (expressed in United States dollars) Independent Auditor's Report To the Shareholders of GeneTether Therapeutics Inc. Opinion We have audited the consolidate...
GeneTether Q4 2023 Press Release v4 March 28 AC edits 1 GeneTether Therapeutics Inc. Announces Fiscal Year 2023 Financial Results and Reports on Corporate Highlights NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Vancouver, British Columbia March 28, 2024 GeneTether Therapeutics...
Date: November 28, 2023 Jurisdictions: Alberta, British Columbia, Ontario
GeneTether Q3 2023 Press Release v3 RB DG PM - DG 11.17.23 1 GeneTether Therapeutics Inc. Announces Third Quarter 2023 Financial Results NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Vancouver, British Columbia November 28, 2023 GeneTether Therapeutics Inc. (together with its wh...
Genetether Q3 CFO 52-109 Certificate (September 30, 2023) (04506898).DOCX {04506898;1} Form 52-109FV2 Certification of Interim Filings Venture Issue Basic Certificate I, Jean Jen, Chief Financial Officer of GeneTether Therapeutics Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together...
Genetether Q3 CEO 52-109 Certificate (September 30, 2023) (04506904).DOCX {04506904;1} Form 52-109FV2 Certification of Interim Filings Venture Issue Basic Certificate I, Roland Boivin, Chief Executive Officer of GeneTether Therapeutics Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (tog...